Logo-jcvtr

J Cardiovasc Thorac Res. 2016;8(1): 26-33. doi: 10.15171/jcvtr.2016.05
PMID: 27069564        PMCID: PMC4827136

Original Article

Cardiac fibrosis and down regulation of GLUT4 in experimental diabetic cardiomyopathy are ameliorated by chronic exposures to intermittent altitude

Mahdi Faramoushi 1, Ramin Amir Sasan 2, Vahid Sari Sarraf 2, Pouran Karimi 3 *

Cited by CrossRef: 13


1- Hadova K, Kralova E, Doka G, Bies Pivackova L, Kmecova Z, Krenek P, Klimas J. Isolated downregulation of HCN2 in ventricles of rats with streptozotocin-induced diabetic cardiomyopathy. BMC Cardiovasc Disord. 2021;21(1) [Crossref]
2- Farajdokht F, Mohaddes G, Karimi-Sales E, Kafshdooz T, Mahmoudi J, Aberoumandi S, Karimi P. Inhibition of PTEN protects PC12 cells against oxygen-glucose deprivation induced cell death through mitoprotection. Brain Research. 2018;1692:100 [Crossref]
3- Suzuki M, Hozumi N, Waki H, Kimura M, Seino T, Onuma N, Shindo D. Effects of combined therapy of ACE inhibitor and exercise on cardiovascular functions and morphology of the heart and kidneys in SHR. JPFSM. 2019;8(5):229 [Crossref]
4- Mohammad Alizadeh E, Mahdavi M, Jenani Fard F, Chamani S, Farajdokht F, Karimi P. Metformin protects PC12 cells against oxygen-glucose deprivation/reperfusion injury. Toxicology Mechanisms and Methods. 2018;28(8):622 [Crossref]
5- Meng K, Cai H, Cai S, Hong Y, Zhang X. Adiponectin Modified BMSCs Alleviate Heart Fibrosis via Inhibition TGF-beta1/Smad in Diabetic Rats. Front Cell Dev Biol. 2021;9 [Crossref]
6- Siques P, Brito J, Flores K, Ordenes S, Arriaza K, Pena E, León-Velarde F, López de Pablo Á, Gonzalez M, Arribas S. Long-Term Chronic Intermittent Hypobaric Hypoxia Induces Glucose Transporter (GLUT4) Translocation Through AMP-Activated Protein Kinase (AMPK) in the Soleus Muscle in Lean Rats. Front Physiol. 2018;9 [Crossref]
7- Idari G, Karimi P, Ghaffari S, Hashemy S, Mashkani B. Protective effects of BiP inducer X (BIX) against diabetic cardiomyopathy in rats. Can J Physiol Pharmacol. 2021;99(6):644 [Crossref]
8- Mallet R, Manukhina E, Ruelas S, Caffrey J, Downey H. Cardioprotection by intermittent hypoxia conditioning: evidence, mechanisms, and therapeutic potential. American Journal of Physiology-Heart and Circulatory Physiology. 2018;315(2):H216 [Crossref]
9- Tao L, Wang L, Yang X, Jiang X, Hua F. Recombinant human glucagon-like peptide-1 protects against chronic intermittent hypoxia by improving myocardial energy metabolism and mitochondrial biogenesis. Molecular and Cellular Endocrinology. 2019;481:95 [Crossref]
10- Pena E, Brito J, El Alam S, Siques P. Oxidative Stress, Kinase Activity and Inflammatory Implications in Right Ventricular Hypertrophy and Heart Failure under Hypobaric Hypoxia. IJMS. 2020;21(17):6421 [Crossref]
11- Nirengi S, Peres Valgas da Silva C, Stanford K. Disruption of energy utilization in diabetic cardiomyopathy; a mini review. Current Opinion in Pharmacology. 2020;54:82 [Crossref]
12- Jia G, Leng B, Wang H, Dai H. Inhibition of cardiotrophin-1 overexpression is involved in the anti-fibrotic effect of Astrogaloside IV. 2017;16(6):8365 [Crossref]
13- Fathi E, Valipour B, Vietor I, Farahzadi R. An overview of the myocardial regeneration potential of cardiac c-Kit+ progenitor cells via PI3K and MAPK signaling pathways. Future Cardiology. 2020;16(3):199 [Crossref]